MKLNF logo

M1 Kliniken AG (MKLNF) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

$'dan işlem gören M1 Kliniken AG (MKLNF), 0 değerindeki bir Healthcare şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 42/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 17 Mar 2026
42/100 AI Puanı

M1 Kliniken AG (MKLNF) Sağlık ve Boru Hattı Genel Bakışı

CEOKilian Brenske
Çalışanlar366
MerkezBerlin, DE
Halka Arz Yılı2021
SektörHealthcare

M1 Kliniken AG, a European and Australian operator of aesthetic and plastic surgery clinics, differentiates itself through its integrated business model encompassing both medical services and the development/distribution of related pharmaceutical products, positioning it within the growing global aesthetic medicine market.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 17 Mar 2026

Yatırım Tezi

M1 Kliniken AG presents an investment case centered on its integrated business model and expansion within the aesthetic medicine market. With a P/E ratio of 15.92 and a dividend yield of 3.29%, the company demonstrates potential value. A key growth catalyst is the increasing demand for aesthetic procedures globally. However, investors may want to evaluate the company's relatively low gross margin of 12.0% and the competitive landscape. The company's beta of 1.14 suggests a slightly higher volatility compared to the market. Further analysis should focus on the company's ability to maintain profitability and expand its market share in a competitive environment.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market capitalization of $0.21 billion indicates its size within the medical care facilities industry.
  • P/E ratio of 15.92 suggests a potentially reasonable valuation compared to its earnings.
  • Dividend yield of 3.29% offers an income component for investors.
  • Profit margin of 5.0% reflects the company's profitability after all expenses.
  • Gross margin of 12.0% indicates the percentage of revenue exceeding the cost of goods sold.

Rakipler & Benzerleri

Güçlü Yönler

  • Established presence in multiple European countries and Australia.
  • Integrated business model with both medical services and product development.
  • Recognized brand in the aesthetic medicine market.
  • Diversified revenue streams from medical procedures and product sales.

Zayıflıklar

  • Relatively low gross margin compared to industry peers.
  • Dependence on consumer spending and discretionary income.
  • Exposure to regulatory changes and healthcare policies.
  • Limited information availability due to OTC listing.

Katalizörler

  • Ongoing: Expansion of M1 Med Beauty centers into new locations.
  • Ongoing: Development and launch of new aesthetic medicine products under the M1 Select brand.
  • Upcoming: Potential acquisitions or partnerships with other healthcare companies.
  • Ongoing: Increasing demand for aesthetic procedures in key markets.
  • Ongoing: Growth of medical tourism and international patient base.

Riskler

  • Potential: Economic downturns and reduced consumer spending on discretionary procedures.
  • Potential: Increased competition from other aesthetic medicine providers.
  • Potential: Changes in healthcare regulations and reimbursement policies.
  • Ongoing: Negative publicity or adverse events affecting the company's reputation.
  • Ongoing: Limited liquidity and price volatility due to OTC listing.

Büyüme Fırsatları

  • Expansion into New Geographic Markets: M1 Kliniken AG has the opportunity to expand its presence into new geographic markets, particularly in regions with growing demand for aesthetic procedures. This expansion could involve establishing new clinics or partnering with existing healthcare providers. The global aesthetic medicine market is projected to reach $147.94 billion by 2030, presenting a substantial opportunity for growth. Timeline: Expansion efforts could begin within the next 1-2 years.
  • Development of New Products and Services: Investing in the development of new and innovative products and services within the aesthetic medicine and cosmetic dermatology fields can drive growth. This could include new treatments, technologies, or product lines that cater to evolving consumer needs. The market for cosmetic dermatology is experiencing continuous innovation, with new products and services being introduced regularly. Timeline: Ongoing, with new product launches expected annually.
  • Increased Focus on Medical Tourism: M1 Kliniken AG can capitalize on the growing trend of medical tourism by attracting patients from other countries seeking affordable and high-quality aesthetic procedures. This could involve marketing its services to international patients and establishing partnerships with travel agencies and tourism organizations. The global medical tourism market is expected to reach $237.7 billion by 2030. Timeline: Can be implemented within the next year.
  • Strategic Acquisitions and Partnerships: Pursuing strategic acquisitions and partnerships with other companies in the healthcare sector can expand M1 Kliniken AG's capabilities and market reach. This could involve acquiring smaller clinics or partnering with pharmaceutical companies to develop and market new products. The healthcare industry is characterized by ongoing consolidation and collaboration. Timeline: Ongoing, with potential acquisitions and partnerships occurring periodically.
  • Enhancement of Digital Marketing and Online Presence: Strengthening its digital marketing efforts and online presence can help M1 Kliniken AG attract more patients and increase brand awareness. This could involve investing in search engine optimization, social media marketing, and online advertising. The majority of consumers now research healthcare services online before making a decision. Timeline: Ongoing, with continuous improvement of digital marketing strategies.

Fırsatlar

  • Expansion into new geographic markets with high demand for aesthetic procedures.
  • Development of new and innovative products and services.
  • Increased focus on medical tourism.
  • Strategic acquisitions and partnerships to expand capabilities.

Tehditler

  • Intense competition from other medical care providers and pharmaceutical companies.
  • Economic downturns and reduced consumer spending.
  • Negative publicity or adverse events affecting the company's reputation.
  • Changes in healthcare regulations and reimbursement policies.

Rekabet Avantajları

  • Established network of medical centers across multiple countries.
  • Integrated business model encompassing both medical services and product development/distribution.
  • Brand recognition and reputation within the aesthetic medicine market.
  • Proprietary products and technologies developed and marketed under the M1 Select brand.

MKLNF Hakkında

Founded in 2007 and based in Berlin, Germany, M1 Kliniken AG has established itself as a provider of aesthetic and plastic surgery services. Operating in two segments, Beauty and Trade, the company's Beauty segment focuses on its network of outpatient specialist centers and specialized surgical clinic centers operating under the M1 Med Beauty brand, totaling 46 specialist centers. These centers offer a range of aesthetic and plastic surgery procedures. The Trade segment develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine and cosmetic dermatology under the M1 Select brand. It also trades in pharmaceutical, biosimilars, and other medical products and devices in areas such as oncology, HIV, rheumatism, neurology, cardiovascular diseases, and narcotics. M1 Kliniken AG extends its business to the acquisition, management, and sale of real estate, primarily within the healthcare sector. The company's geographic footprint spans Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. M1 Kliniken AG operates as a subsidiary of MPH Health Care AG.

Ne Yaparlar

  • Operates medical centers for aesthetic and plastic surgery.
  • Develops and markets pharmaceutical, medical, and medical technology products.
  • Trades in pharmaceutical, biosimilars, and other medical products.
  • Offers products to doctors, pharmacies, and wholesalers under the M1 Select brand.
  • Manages a network of outpatient specialist centers.
  • Operates a specialized surgical clinic center.
  • Engages in the acquisition, management, and sale of real estate in the healthcare sector.

İş Modeli

  • Generates revenue from aesthetic and plastic surgery procedures performed at its medical centers.
  • Generates revenue from the sale of pharmaceutical, medical, and medical technology products.
  • Generates revenue from trading in pharmaceutical, biosimilars, and other medical products.

Sektör Bağlamı

M1 Kliniken AG operates within the medical care facilities industry, which is experiencing growth driven by increasing demand for aesthetic and plastic surgery. The global aesthetic medicine market is projected to reach significant growth by 2030. The competitive landscape includes other medical care providers and pharmaceutical companies. M1 Kliniken AG differentiates itself through its integrated model, combining medical services with the development and distribution of related products. The company's success depends on its ability to adapt to changing consumer preferences and regulatory requirements.

Kilit Müşteriler

  • Individuals seeking aesthetic and plastic surgery procedures.
  • Doctors, pharmacies, and wholesalers who purchase the company's products.
  • Patients requiring pharmaceutical and medical products in areas such as oncology, HIV, rheumatism, neurology, and cardiovascular diseases.
AI Güveni: 69% Güncellendi: 17 Mar 2026

Finansallar

Grafik & Bilgi

M1 Kliniken AG (MKLNF) hisse senedi fiyatı: Price data unavailable

Son Haberler

MKLNF için son haber bulunmamaktadır.

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

MKLNF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

MKLNF için Wall Street fiyat hedefi analizi.

MoonshotScore

42/100

Bu puan ne anlama geliyor?

MoonshotScore, MKLNF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Kilian Brenske

Unknown

Information on Kilian Brenske's background is not available in the provided context. Further research would be needed to detail his career history, education, and previous roles.

Sicil: Information on Kilian Brenske's track record is not available in the provided context. Further research would be needed to assess his achievements and strategic decisions as CEO.

MKLNF OTC Piyasa Bilgileri

The OTC Other tier, where M1 Kliniken AG trades, represents the lowest tier of the OTC market. Companies in this tier may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. This often indicates limited regulatory oversight and potentially higher risks compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should be aware that companies on the OTC Other tier may have limited information available and may not be subject to the same level of scrutiny as exchange-listed companies.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: Liquidity for M1 Kliniken AG on the OTC market is likely limited. OTC stocks generally have lower trading volumes and wider bid-ask spreads compared to exchange-listed stocks. This can make it more difficult to buy or sell shares quickly and at a desired price. Investors should be prepared for potential price volatility and illiquidity when trading MKLNF on the OTC market.
OTC Risk Faktörleri:
  • Limited financial disclosure due to OTC listing.
  • Lower liquidity and potential price volatility.
  • Higher risk of fraud or manipulation compared to exchange-listed stocks.
  • Limited regulatory oversight and investor protection.
  • Potential difficulties in obtaining accurate and timely information.
Durum Tespiti Kontrol Listesi:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the background and experience of the company's management team.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's regulatory compliance and legal risks.
  • Review the company's shareholder structure and ownership.
  • Consult with a qualified financial advisor before investing.
  • Understand the risks associated with investing in OTC stocks.
Meşruiyet Sinyalleri:
  • Established business operations in multiple countries.
  • Audited financial statements (if available).
  • Presence of a recognized brand in the aesthetic medicine market.
  • Membership in industry associations or trade groups.
  • Positive customer reviews and testimonials.

MKLNF Hakkında Sıkça Sorulan Sorular

MKLNF için değerlendirilmesi gereken temel faktörler nelerdir?

M1 Kliniken AG (MKLNF) şu anda yapay zeka skoru 42/100, düşük puanı gösteriyor. Temel güçlü yan: Established presence in multiple European countries and Australia.. İzlenmesi gereken birincil risk: Potential: Economic downturns and reduced consumer spending on discretionary procedures.. Bu bir finansal tavsiye değildir.

MKLNF MoonshotScore'u nedir?

MKLNF şu anda MoonshotScore'da 42/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

MKLNF verileri ne sıklıkla güncellenir?

MKLNF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler MKLNF hakkında ne diyor?

MKLNF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

MKLNF'a yatırım yapmanın riskleri nelerdir?

MKLNF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Economic downturns and reduced consumer spending on discretionary procedures.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

MKLNF'ın P/E oranı nedir?

MKLNF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için MKLNF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

MKLNF aşırı değerli mi, yoksa düşük değerli mi?

M1 Kliniken AG (MKLNF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

MKLNF'ın temettü verimi nedir?

M1 Kliniken AG (MKLNF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Limited information available for OTC-listed companies.
  • Analyst consensus may not be readily available.
Veri Kaynakları

Popüler Hisseler